Dr. Kutlwano Xulu

Kutlwano Xulu is a cancer researcher whose work centers on breast cancer biology, with particular emphasis on hormone-responsive subtypes and their interaction with the coagulation system. Published in journals such as Scientific Reports, Frontiers in Genetics, and International Journal of Molecular Sciences, this research explores how tumour cells adapt to endocrine therapy and blood-derived factors within the tumour microenvironment.

A consistent theme across the publications is the interplay between platelet activation, hypercoagulation, and epithelial–mesenchymal transition. Through in vitro co-culture models, ultrastructural analysis, and molecular profiling, these studies demonstrate how combined hormone and antiplatelet therapies may unintentionally promote tumour cell survival, partial EMT, and aggressive phenotypes in luminal breast cancer cells.

Review contributions further highlight expertise in tumour heterogeneity, stemness, and evolution-informed precision oncology. By integrating concepts of Darwinian selection with biomarker discovery and secretome analysis, this body of work advances understanding of treatment resistance, tumour progression, and the clinical implications of targeting platelet pathways in breast cancer management.